Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

An appeals court in Missouri has lowered the damages awarded to women who claimed that Johnson & Johnson’s (NYSE: JNJ) baby powder caused their cancer diagnosis to $2.12 billion.

Johnson & Johnson Damages Halved To $2.12B By Court In Missouri But Verdict Stands

A Missouri appeals court on Tuesday reduced a damages award against Johnson & Johnson to about $2.12 billion from $4.69 billion in a case brought by 22 women who blamed their ovarian cancer on asbestos in its baby powder and other talc products. The Missouri Court of Appeals awarded $500 million in actual damages and.

Johnson & Johnson damages cut in half in talcum powder cancer suit

A Missouri appeals court on Tuesday rejected Johnson & Johnson's bid to throw out a jury verdict in favor of women who blamed their ovarian cancer on its baby powder and other talc products, but reduced its damages award to $2.12 billion from $4.69 billion.

J&J loses bid to overturn baby powder verdict, but damages cut to $2.1 billion

A Missouri appeals court on Tuesday reduced a damages award against Johnson & Johnson to about $2.12 billion from $4.69 billion in a case brought by 22 women who blamed their ovarian cancer on asbestos in its baby powder and other talc products.

Damages verdict against Johnson & Johnson lowered to $2.1 billion in Missouri talc case

AstraZeneca

GlaxoSmithKline

Moderna

Novavax

Pfizer

Globally, there are more than 100 vaccines under development - with nine of them in human clinical trials already.

Who's Ahead In Finding A COVID-19 Vaccine?

Cisco Systems

Coca-Cola

After an impressive rally from March lows, many stocks may be ready to take a breather. Yet there are several Dow Jones companies to buy as volatility returns to the market.

3 Dow Jones Companies to Buy as Markets Get Volatile

It seems that just about everyone — Germany, France, Italy, the Netherlands, the U.S.

EU, Johnson & Johnson In Coronavirus Vaccine Talks: Report

The European Commission is in advanced talks with pharmaceutical giant Johnson & Johnson to reserve or buy up-front doses of its COVID-19 vaccine under development, two officials familiar with the talks told Reuters.

Exclusive: EU in advanced talks with Johnson & Johnson on COVID-19 vaccine deal - sources

Johnson & Johnson has been a spectacular dividend king.

Retirement Strategy: A Safe Dividend King With An Upside Potential Of Nearly 50%

Even after the novel coronavirus is contained, healthcare stocks will remain in focus. Good time to accumulate stocks with strong growth outlook.

3 Top Healthcare Stocks for a More Aware World

BioNTech SE

Emergent BioSolutions

Merck

Globally, there are more than 100 vaccines under development — with nine of them in human clinical trials already, asserts equity analyst Sel Hardy, in CFRA Research's flagship newsletter, The Outlook.

9 Pharmaceutical Companies Racing For A COVID-19 Vaccine

Anheuser-Busch InBev

Kinder Morgan

NetApp

Shaw Communications

These cheap GARP stocks have huge upside potential with attractive yields, and wise investors should not ignore them.

5 Cheap Growth Stocks With Attractive Dividend Yields

Inovio Pharmaceuticals

Some of the earliest novel coronavirus (COVID-19) vaccines to be approved are more likely to target prevention against developing severe symptoms from catching the virus, rather than the initial infection, multiple health experts told Bloomberg.

Early Coronavirus Vaccines Likely To Target Further Complications, Not Infection, Health Experts Say

Microsoft

Walmart

If you're feeling jittery, these stocks will help you sleep easy at night.

3 Rock Solid Dividend Stocks That Won't Flinch if the Market Crashes Again

Apple

Amazon

Clorox

Shopify

These top stocks can help you safeguard and grow your wealth during the coronavirus pandemic.

Stock Market Crash: Where to Invest Your Money Now

Johnson & Johnson is hoping to tackle the new form of coronavirus with a vaccine, but the pharma giant is still facing litigation challenges. Is JNJ stock a buy right now?

Is Johnson & Johnson Stock A Buy As Pressure Mounts For A Coronavirus Vaccine?

J&J's (JNJ) goal is to supply more than 1 billion doses of the vaccine globally if it proves to be safe and effective.

J&J to Begin Human Study on Coronavirus Vaccine in July

Colgate-Palmolive

DocuSign

Grocery Outlet

Kimberly-Clark

Zoom Video

The Fed now expects the U.S. unemployment rate to hit 9.3% this year and sees American GDP falling by 6.5% in 2020.

Fed Sparks Economic Concerns: Winning Investment Strategies

Johnson & Johnson (NYSE: JNJ) will begin the human clinical trials of its novel coronavirus (COVID-19) vaccine in July, the company announced Wednesday.

Johnson & Johnson To Start Coronavirus Vaccine Human Trials Ahead Of Schedule In July

The healthcare giant's COVID-19 vaccine program is moving forward more quickly than expected.

Johnson & Johnson to Begin Coronavirus Vaccine Clinical Trial in July

Johnson & Johnson (NYSE: JNJ) has announced that it will accelerate initiation of its early stage first-in-human clinical trial for the treatment of COVID-19.

Johnson & Johnson Accelerates Its COVID-19 Vaccine Hopes

Shares of Johnson & Johnson jnj rallied 1.3% in morning trading Wednesday, after the drug maker said it has accelerated the initiation of the phase 1/2a first-in-human clinical trial of Ad26.COV2-S, which is its investigational SARS-CoV-2 vaccine.

Johnson & Johnson accelerates initiation of human trial of COVID-19 virus vaccine

J&J said it is committed to the goal of supplying more than one billion doses globally through the course of 2021.

Johnson & Johnson to begin human trials for coronavirus vaccine in late July, earlier than expected

Johnson & Johnson  said on Wednesday it would start human trials of its potential COVID-19 vaccine in the second half of July.

J&J to begin human trials of COVID-19 vaccine in second half of July

NEW BRUNSWICK, N.J., June 10, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2a first-in-human clinical trial of its investigational SARS-CoV-2...

News for Johnson & Johnson Stock (JNJ)